Based on the team's discovery that an enzyme called CD38, implicated in aging metabolism, is elevated in scleroderma and ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

A recent Phase II trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce ...

The French pharma group has filed anti-CD38 antibody Sarclisa (isatuximab) for use in combination with Takeda’s Velcade (bortezomib), lenalidomide, and dexamethasone – known as the VRd regimen ...

In addition, the J&J anti-CD38 antibody also reduced the risk of needing first-line multiple myeloma treatment by 42% compared with active monitoring. As of the data cutoff, 64 patients (33% ...

and anti-CD38 antibodies. Equecabtagene autoleucel (eque-cel), an investigative fully human-derived B-cell maturation antigen (BCMA)–targeting chimeric antigen receptor (CAR) T-cell therapy ...